ORPH Falls From Speculative Surge After FDA Rejection

Orphazyme was briefly a victim of the meme stock frenzy

Digital Content Manager
Jun 18, 2021 at 9:53 AM
facebook X logo linkedin

The shares of Orphazyme A S ADR (NASDAQ:ORPH) are dramatically lower this morning, slammed by news that the Food and Drug Administration (FDA) rejected the firm's experimental genetic disorder drug candidate, arimoclomol. The Danish biotech has recently been dubbed a meme stock, surging to an unprecedented high of $77.77 earlier in the month. One analyst from Nordnet now calls the situation "hopeless," as the FDA's decision has left ORPH with no money or documentable projects, adding that its "game over for 'meme speculation'."

The security was last seen down 38.9%  at $8.40, putting it even closer to its lows near the $5 level. ORPH just breached its 70-day moving average, too, which looked for a second like it could support the stock's pullback from its early June surge. Orphazyme stock is still up 57.5% in the last month, however. 

This drop could lead to price-target cuts. The 12-month consensus price target of $10.50 is a whopping 45.8% to last night's close. Meanwhile, of the three analysts in coverage, there is only one "buy" rating  on the books. 

While short interest has waned from its March highs, it shot up in the last reporting period to 35,295 shares sold short. There's a good possibility more short sellers will pile on, should this negative price action continue, as these shares only make up 0.1% of the stock's available float. It should be noted, however, ORPH has landed on the short-sell restricted (SSR) list today. 



Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI